Cancer Research Cancer Epigenetics Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sauer, L. A.
Right arrow Articles by Blask, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sauer, L. A.
Right arrow Articles by Blask, D. E.
[Cancer Research 60, 5289-5295, September 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Mechanism for the Antitumor and Anticachectic Effects of n-3 Fatty Acids1

Leonard A. Sauer2, Robert T. Dauchy and David E. Blask

Bassett Research Institute, Cooperstown, New York 13326

Dietary intake of the n-6 fatty acid (FA) linoleic acid (LA) has a strong growth-promoting effect on many rodent tumors and human tumor xenografts grown in immunodeficient rodents. n-3 FAs such as {alpha}-linolenic and eicosapentaenoic acids (EPAs), which differ from LA and arachidonic acid, respectively, by only a single double bond in the n-3 position, are recognized cancer chemopreventive and anticachectic agents. Understanding how this seemingly small structural difference leads to such remarkable functional differences has been a challenge. In a previous study, we showed that LA uptake, [3H]thymidine incorporation into DNA, and total DNA content were decreased in tissue-isolated hepatoma 7288CTC perfused in situ with arterial blood containing {alpha}-linolenic acid, EPA, or docosahexaenoic acids. The Ki for the inhibition of LA uptake and [3H]thymidine incorporation by {alpha}-linolenic acid was 0.18 and 0.25 mM, respectively. Here we show that the addition of {alpha}-linolenic acid or EPA to arterial blood inhibits tumor FA uptake, including LA, and the subsequent conversion of LA to the mitogen 13-hydroxyoctadecadienoic acid (13-HODE) in vivo and during perfusion in situ. [3H]Thymidine incorporation during perfusion in situ was also inhibited. Addition of 13-HODE to the arterial blood reversed the inhibition of [3H]thymidine incorporation but had no effect on FA uptake. These two n-3 FAs also inhibited FA transport in inguinal fat pads in vivo and during perfusion in situ in fed (FA uptake) and fasted (FA release) rats. The effects of EPA and {alpha}-linolenic acid on transport of saturated, monounsaturated, and n-6 polyunsaturated FAs in hepatoma 7288CTC and inguinal fat pads during perfusion in situ were reversed by the addition of forskolin (1 µM), pertussis toxin (0.5 µg/ml), or 8-bromo-cyclic AMP (10 µM) to the arterial blood. We conclude that the antitumor and anticachectic effects of n-3 FAs on hepatoma 7288CTC and inguinal fat pads in vivo result from an inhibition of FA transport. These inhibitions are mediated by a putative n-3 FA receptor via a Gi protein-coupled signal transduction pathway that decreases intracellular cyclic AMP. A specific decrease in LA uptake and its conversion to the mitogen 13-HODE causes the tumor growth inhibition.




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
P. Wellendorph, L. D. Johansen, and H. Brauner-Osborne
Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients
Mol. Pharmacol., September 1, 2009; 76(3): 453 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
Y. Liu, Z. Jia, L. Dong, R. Wang, and G. Qiu
A Randomized Pilot Study of Atractylenolide I on Gastric Cancer Cachexia Patients
Evid. Based Complement. Altern. Med., September 1, 2008; 5(3): 337 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. N. Fedorov, L. K. Shubina, A. M. Bode, V. A. Stonik, and Z. Dong
Dactylone Inhibits Epidermal Growth Factor-Induced Transformation and Phenotype Expression of Human Cancer Cells and Induces G1-S Arrest and Apoptosis
Cancer Res., June 15, 2007; 67(12): 5914 - 5920.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, and E. M. Dauchy
Eicosapentaenoic Acid Suppresses Cell Proliferation in MCF-7 Human Breast Cancer Xenografts in Nude Rats via a Pertussis Toxin-Sensitive Signal Transduction Pathway
J. Nutr., September 1, 2005; 135(9): 2124 - 2129.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Hardy, G. G. St-Onge, E. Joly, Y. Langelier, and M. Prentki
Oleate Promotes the Proliferation of Breast Cancer Cells via the G Protein-coupled Receptor GPR40
J. Biol. Chem., April 8, 2005; 280(14): 13285 - 13291.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Calviello, F. Di Nicuolo, S. Gragnoli, E. Piccioni, S. Serini, N. Maggiano, G. Tringali, P. Navarra, F. O. Ranelletti, and P. Palozza
n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1{alpha} induction pathway
Carcinogenesis, December 1, 2004; 25(12): 2303 - 2310.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, E. M. Dauchy, K. J. Welham, and K. Coupland
Conjugated Linoleic Acid Isomers and Trans Fatty Acids Inhibit Fatty Acid Transport in Hepatoma 7288CTC and Inguinal Fat Pads in Buffalo Rats
J. Nutr., August 1, 2004; 134(8): 1989 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Sparreboom, A. C. Wolff, J. Verweij, Y. Zabelina, D. M. van Zomeren, G. L. McIntire, C. S. Swindell, R. C. Donehower, and S. D. Baker
Disposition of Docosahexaenoic Acid-Paclitaxel, a Novel Taxane, in Blood: In Vitro and Clinical Pharmacokinetic Studies
Clin. Cancer Res., January 1, 2003; 9(1): 151 - 159.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
P. J. Jones
Clinical nutrition: 7. Functional foods -- more than just nutrition
Can. Med. Assoc. J., June 1, 2002; 166(12): 1555 - 1563.
[Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
M. P. Davis and E. D. Dickerson
Thalidomide: Dual benefits in palliative medicine and oncology
American Journal of Hospice and Palliative Medicine, September 1, 2001; 18(5): 347 - 351.
[Abstract] [PDF]

Home page
 J. Lipid Res.Home page
R. J. Pawlosky, J. R. Hibbeln, J. A. Novotny, and N. Salem Jr.
Physiological compartmental analysis of {alpha}-linolenic acid metabolism in adult humans
J. Lipid Res., August 1, 2001; 42(8): 1257 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. E. Hardman, C. P. R. Avula, G. Fernandes, and I. L. Cameron
Three Percent Dietary Fish Oil Concentrate Increased Efficacy of Doxorubicin Against MDA-MB 231 Breast Cancer Xenografts
Clin. Cancer Res., July 1, 2001; 7(7): 2041 - 2049.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Liu, D. M. Bibus, A. M. Bode, W.-Y. Ma, R. T. Holman, and Z. Dong
Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells
PNAS, June 19, 2001; 98(13): 7510 - 7515.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.